- Home
- VRDN vs TARS Comparison
VRDN vs TARS Comparison
Compare VRDN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- TARS
- Stock Information
- Founded
- VRDN 2006
- TARS 2016
- Country
- VRDN United States
- TARS United States
- Employees
- VRDN N/A
- TARS N/A
- Industry
- VRDN Medical Specialities
- TARS Medicinal Chemicals and Botanical Products
- Sector
- VRDN Health Care
- TARS Health Care
- Exchange
- VRDN Nasdaq
- TARS Nasdaq
- Market Cap
- VRDN 1.5B
- TARS 1.7B
- IPO Year
- VRDN N/A
- TARS 2020
- Fundamental
- Price
- VRDN $18.87
- TARS $49.36
- Analyst Decision
- VRDN Strong Buy
- TARS Strong Buy
- Analyst Count
- VRDN 11
- TARS 7
- Target Price
- VRDN $38.80
- TARS $67.14
- AVG Volume (30 Days)
- VRDN 877.5K
- TARS 690.2K
- Earning Date
- VRDN 11-11-2025
- TARS 11-12-2025
- Dividend Yield
- VRDN N/A
- TARS N/A
- EPS Growth
- VRDN N/A
- TARS N/A
- EPS
- VRDN N/A
- TARS N/A
- Revenue
- VRDN $305,000.00
- TARS $295,521,000.00
- Revenue This Year
- VRDN N/A
- TARS $33,170.29
- Revenue Next Year
- VRDN $35,092.81
- TARS N/A
- P/E Ratio
- VRDN N/A
- TARS N/A
- Revenue Growth
- VRDN 5.90
- TARS 254.45
- 52 Week Low
- VRDN $9.90
- TARS $30.23
- 52 Week High
- VRDN $27.20
- TARS $59.76
- Technical
- Relative Strength Index (RSI)
- VRDN 52.46
- TARS 36.86
- Support Level
- VRDN $18.12
- TARS $55.45
- Resistance Level
- VRDN $20.51
- TARS $59.76
- Average True Range (ATR)
- VRDN 0.94
- TARS 2.01
- MACD
- VRDN -0.01
- TARS -1.34
- Stochastic Oscillator
- VRDN 34.66
- TARS 8.77
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.